68. Hoffman R., Welton M.L., Klencke B., Weinberg V., Krieg R. The significance of pretreatment CD4 count on the outcome and treatment tolerance of HIV-positive patients with anal cancer. Int J Radiat Oncol Biol Phys 1999;44(1):127–31.
69. John M., Pajak T., Flam M., Hoffman J., Markoe A., Wolkov H., Paris K. Dose escalation in chemoradiation for anal cancer: preliminary results of RTOG 92-08. Cancer J Sci Am 1996;2(4):205–11.
70. Wexler A., Berson A.M., Goldstone S.E., Waltzman R., Penzer J., Maisonet O.G., McDermott B., Rescigno J. Invasive anal squamous-cell carcinoma in the HIV-positive patient: outcome in the era of highly active antiretroviral therapy. Dis Colon Rectum 2008;51(1):73–81.
71. Edelman S., Johnstone P.A. Combined modality therapy for HIV-infected patients with squamous cell carcinoma of the anus: outcomes and toxicities. Int J Radiat Oncol Biol Phys 2006;66(1):206–11.
72. Kouloulias V., Plataniotis G., Kouvaris J., Dardoufas C., Gennatas C., Uzunoglu N., Papavasiliou C., Vlahos L. Chemoradiotherapy combined with intracavitary hyperthermia for anal cancer: feasibility and long-term results from a phase II randomized trial. Am J Clin Oncol 2005;28(1):91–9.
73. Ott O.J., Schmidt M., Semrau S., Strnad V., Matzel K.E., Schneider I., Raptis D.,
Uter W., Grützmann R., Fietkau R. Chemoradiotherapy with and without deep regional hyperthermia for squamous cell carcinoma of the anus. Strahlenther Onkol 2019;195(7):607–14.
74. Leon O., Guren M., Hagberg O., Glimelius B., Dahl O., Havsteen H., Naucler G., Svensson C., Tveit K.M., Jakobsen A., Pfeiffer P., Wanderås E., Ekman T., Lindh B.,
Balteskard L., Frykholm G., Johnsson A. Anal carcinoma – Survival and recurrence in a large cohort of patients treated according to Nordic guidelines. Radiother Oncol 2014;113(3):352–8.
75. Freshwater T., Kondic A., Ahamadi M., Li C.H., de Greef R., de Alwis D., Stone J.A. Evaluation of dosing strategy for pembrolizumab for oncology indications. J Immunother Cancer 2017;5:43.
76. Marabelle A., Cassier P.A., Fakih M., Kao S., Nielsen D., Italiano A., Guren T.K.,
van Dongen M.G.J., Spencer K., Bariani G.M., Ascierto P.A., Santoro A., Shah M., Asselah J., Iqbal S., Takahashi S., Piha-Paul S.A., Ott P.A., Chatterjee A., Jin F., Norwood K., Delord J.P. Pembrolizumab for previously treated advanced anal squamous cell carcinoma: results from the non-randomised, multicohort, multicentre, phase 2 KEYNOTE-158 study. Lancet Gastroenterol Hepatol 2022;7(5):446–54.
77. Bei D., Osawa M., Uemura S., Ohno T., Gobburu J., Roy A., Hasegawa M. Benefit-risk assessment of nivolumab 240 mg flat dose relative to 3 mg/kg Q2W regimen in Japanese patients with advanced cancers. Cancer Sci 2020;111(2):528–35.
78. De Dosso S., Martin V., Zanellato E., Frattini M., Saletti P. Molecular characterization and response to cetuximab in a patient with refractory squamous cell anal carcinoma. Tumori 2010;96(4):627–8.
79. Phan L.K., Hoff P.M. Evidence of clinical activity for cetuximab combined with irinotecan in a patient with refractory anal canal squamous-cell carcinoma: report of a case.
Dis Colon Rectum 2007;50(3):395–8.
80. Tabernero J., Pfeiffer P., Cervantes A. Administration of cetuximab every 2 weeks in the treatment of metastatic colorectal cancer: an effective, more convenient alternative to weekly administration? Oncologist 2008;13(2):113–9.
81. Parikh A.R., Gonzalez-Gugel E., Smolyakova N., Jen M.H., Toms N., Lin Y., Kim J.S., Kopetz S. Efficacy and Safety of Cetuximab Dosing (biweekly vs weekly) in Patients with KRAS Wild-type Metastatic Colorectal Cancer: A Meta-analysis. Oncologist 2022;27(5):371–9.
82. Addeo R., Montella L., Mastella A., Vincenzi B., Mazzone S., Ricciardiello F.,
Del Prete S. Maintenance Therapy with Biweekly Cetuximab: Optimizing Schedule Can Preserve Activity and Improves Compliance in Advanced Head and Neck Cancer. Oncology 2018;95(6):353–9.
83. Phan LK, Hoff PM. Evidence of clinical activity for cetuximab combined with irinotecan in a patient with refractory anal canal squamous-cell carcinoma: report of a case. Diseases of the colon & rectum. 2007 Mar;50:395-8.
84. Kim DW, Byer J, Kothari N, Mahipal A, Chang YD, Kim RD. EGFR inhibitors in patients with advanced squamous cell anal carcinomas: a single-institution experience. Oncology. 2017 Feb 3;92(4):190-6.
85. Kim S. et al. Atezolizumab plus modified DCF (docetaxel, cisplatin, and 5-fluorouracil) as first-line treatment for metastatic or locally advanced squamous cell anal carcinoma: A SCARCE-PRODIGE 60 randomized phase II study. 2022;40:3508-3508.
86. Tessier, L., et al., Laparoscopic ovarian transposition prior to pelvic radiation in young women with anorectal malignancies: a systematic review and meta-analysis of prevalence. Colorectal Dis. 2023;25(7):1336-1348.
87. Deli T, Orosz M, Jakab A. Hormone Replacement Therapy in Cancer Survivors - Review of the Literature. Pathol Oncol Res. 2020;26(1):63-78.
88. Hoel, D. G., et al. The risks and benefits of sun exposure 2016. Dermato-endocrinology. 2016;8(1).
89. Bregar, A., Taylor, K., & Stuckey, A. Hormone therapy in survivors of gynaecological and breast cancer. The Obstetrician & Gynaecologist. 2014;16(4):251-258.
90. Maltser S, Cristian A, Silver JK, Morris GS, Stout NL. A focused review of safety considerations in cancer rehabilitation. PM&R. 2017;9(9):415-28.
91. Derksen JW, Beijer S, Koopman M, Verkooijen HM, van de Poll-Franse LV, May AM. Monitoring potentially modifiable lifestyle factors in cancer survivors: a narrative review on currently available methodologies and innovations for large-scale surveillance. European Journal of Cancer. 2018;103:327-40.
92. Arem H, Loftfield E. Cancer epidemiology: a survey of modifiable risk factors for prevention and survivorship. American journal of lifestyle medicine. 2018;12(3):200-10.
93. Vijayvergia N, Denlinger CS. Lifestyle factors in cancer survivorship: where we are and where we are headed. Journal of personalized medicine. 2015;5(3):243-63.